Second-line combination antiretroviral therapy in resource-limited settings: facing the challenges through clinical research
- 1 July 2007
- journal article
- review article
- Published by Wolters Kluwer Health in AIDS
- Vol. 21 (Suppl 4) , S55-S63
- https://doi.org/10.1097/01.aids.0000279707.01557.b2
Abstract
Combination antiretroviral therapy (ART) has dramatically altered the prognosis of individuals infected with HIV. In the past 5 years there has been a concerted effort to increase access to ART in the developing world. The evidence to date suggests that adherence to therapy and clinical outcomes in developing world programmes are at least the equal of those observed in developed countries. Although access to first-line therapy is reasonably well established, there is a substantial and unacceptable mortality rate in the first 6 months after initiation of ART, particularly in those with low CD4 cell counts and late-stage disease. Failure of first-line ART is inevitable in a proportion of patients. Access to second-line ART regimens in developing countries is problematic, mainly because of the expense of HIV protease inhibitors (PIs). Access to second-line ART may be facilitated by novel strategies using the existing recommended agents or by the use of new agents or classes. Refinement of programmes in the developing world must be underpinned by the same rigorous scientific research effort that has characterized the success of the effort in the developed world. Therefore, the funding bodies responsible for the roll-out of antiretroviral access across the globe must mandate, incorporate and fund clinical research as an intrinsic aspect of combination ART roll-out programmes.Keywords
This publication has 58 references indexed in Scilit:
- A Novel Substrate-Based HIV-1 Protease Inhibitor Drug Resistance MechanismPLoS Medicine, 2007
- Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South AfricaPublished by Elsevier ,2006
- Rapid Scale-up of Antiretroviral Therapy at Primary Care Sites in ZambiaJAMA, 2006
- Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trialThe Lancet, 2006
- Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sectorAIDS, 2006
- Free Antiretrovirals Must Not Be Restricted Only to Treatment-Naive PatientsPLoS Medicine, 2005
- Indinavir/ritonavir‐based therapy in HIV‐1‐infected antiretroviral therapy‐naive patients: comparison of 800/100 mg and 400/100 mg twice dailyHIV Medicine, 2005
- Scaling up access to antiretroviral treatment in southern Africa: who will do the job?The Lancet, 2004
- Antiretroviral therapy in AfricaBMJ, 2004
- Changing patterns of mortality across Europe in patients infected with HIV-1The Lancet, 1998